Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02125877 · ClinicalTrials.gov registry record · Phase 2
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 173
- Enrollment target
NCT02125877: Completed Phase 2 study, sponsored by Novartis Pharmaceuticals.
NCT02125877 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 173 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (30% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02125877, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 173 participants
- Enrollment target
Study Summary
Assessed the new film-coated tablet formulation to the currently approved dispersible tablet formulation with regards to overall safety, Gastrointestinal (GI) tolerability, palatability, satisfaction and compliance
Primary Outcome
The percentage of participants with adverse events, serious adverse events and deaths was assessed.
Interventions
- DRUG Deferasirox dispersible tablet
- DRUG Defearisox film-coated tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 2014-07-08 |
| Est. Completion | 2016-02-24 |
| Phase | Phase 2 |
What the finished NCT02125877 record still lists
NCT02125877 is an interventional study that assigns participants to a tested intervention. The registered 173 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (30% higher).
The record links to 0 conditions, and to 2 interventions - of which Deferasirox dispersible tablet is the first listed.
NCT02125877 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02125877 about?
NCT02125877 is a clinical study titled "Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)". Assessed the new film-coated tablet formulation to the currently approved dispersible tablet formulation with regards to overall safety, Gastrointestinal (GI) tolerability, palatability, satisfaction and compliance
What is the current status of trial NCT02125877?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 173 participants. The study started on 2014-07-08. Estimated completion is 2016-02-24.
What interventions are being tested in trial NCT02125877?
The interventions under investigation include: Deferasirox dispersible tablet (DRUG), Defearisox film-coated tablet (DRUG).
Who is sponsoring clinical trial NCT02125877?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02125877's enrollment target sits among peer trials
173 397th of 2000 higher than 1,604 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05568719 · 173 participants · Phase 3
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
- NCT07070115 · 173 participants · NA
Evaluating Clinical Hiatal Hernia Outcomes Using OviTex®
- NCT07150832 · 173 participants · NA
Efficacy of the I-CARE Digital Health Intervention
- NCT01000259 · 174 participants
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI